Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Neurology Clinical Trials Innovation

Sunovion’s TAAR1 Agonist Brings Something New To CNS Arena

‘Exciting Step Forward’?

  • Analysis

Executive Summary

Sunovion’s new schizophrenia candidate is generating investor attention given its first-in-class mode of action. Newly published clinical results appear to bear out its promise in a sector where there’s been limited innovation.

You may also be interested in...



Sumitomo, Otsuka Both Stand To Gain From CNS Partnership

Sumitomo’s Sunovion has made particular headway in the TAAR1 agonist field and stands to benefit from Otsuka’s CNS expertise and overseas marketing heft.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: ripples from SVB’s failure; Karuna’s schizophrenia win; big pharma remains open to partnering; ChatGPT comes to medical congresses; and China’s COVID vaccine lessons.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: Leqembi bodes well for Biogen; AbbVie predicts US Humira erosion; Sanofi’s R&D chief moves on; Roche’s ophthalmology plans; and Scrip Asks what 2023 holds for AI in pharma.

Table

View full table

Topics

Related Companies

Tags:
Neurology Clinical Trials Innovation
Latest Headlines

First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands

ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach

Investors Take Flight After Bluebird Bio’s Sickle Cell Delay

Roche Continues To Cast Its Collaborations Net Wide

See All
UsernamePublicRestriction

Register

SC142054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By